Related Experiment Videos
Modulation of [3H]glibenclamide binding to cardiac and insulinoma membranes
J F French1, L C Riera, U L Mullins
1Bristol-Myers Squibb Pharmaceutical Research Institute, Cardiovascular Pharmacology, Wallingford, CT 06492.
Abstract:
The existence of a single or of multiple populations of glibenclamide binding sites is a subject of controversy. In the present study, radioligand binding techniques were employed to determine whether multiple populations of [3H]glibenclamide binding sites exist in pancreatic tumor (insulinoma) cells. Additional studies were performed to further characterize the binding of [3H]glibenclamide to insulinoma and cardiac membranes. [3H]Glibenclamide bound to high (0.1 nM) and low (240 nM) affinity binding sites in insulinoma membranes. The physiological relevance of multiple populations of sites is unknown. The binding of glibenclamide to insulinoma and cardiac membranes was altered by guanine nucleotides and not adenine nucleotides. This suggests glibenclamide binding can be modulated by G-proteins. Glibenclamide binding was also modulated by divalent cations. The divalent cations, Ca2+ and Zn2+, stimulated specific glibenclamide binding to cardiac and insulinoma membranes, while Mg2+ and Mn2+ enhanced cardiac binding only. Moreover, the lowering of pH from 7.4 to 6.5 was found to enhance specific glibenclamide binding. Interestingly, the magnitude of this effect was much larger in cardiac membranes. The specific nature of the regulation of glibenclamide binding by guanine nucleotides, divalent cations and pH remains to be explored.
Insights
This study reveals glibenclamide binds to both high and low affinity sites in insulinoma cells, suggesting multiple binding populations. G-proteins, cations, and pH influence this binding, warranting further investigation into its physiological relevance.
Area of Science:
- Pharmacology
- Cell Biology
- Biochemistry
Background:
- The precise number and affinity of glibenclamide binding sites remain debated.
- Glibenclamide is a key drug used in treating type 2 diabetes.
Purpose of the Study:
- To investigate the existence of multiple [3H]glibenclamide binding sites in pancreatic tumor (insulinoma) cells.
- To characterize glibenclamide binding in insulinoma and cardiac membranes.
Main Methods:
- Radioligand binding assays using [3H]glibenclamide.
- Analysis of glibenclamide binding in insulinoma and cardiac membranes under varying conditions (nucleotides, cations, pH).
Main Results:
- [3H]Glibenclamide identified both high (0.1 nM) and low (240 nM) affinity binding sites in insulinoma membranes.
- Guanine nucleotides, but not adenine nucleotides, modulated glibenclamide binding, suggesting G-protein involvement.
- Divalent cations (Ca2+, Zn2+, Mg2+, Mn2+) and pH influenced glibenclamide binding differently in cardiac and insulinoma membranes.
Conclusions:
- Evidence suggests multiple glibenclamide binding sites exist in insulinoma cells.
- Glibenclamide binding is modulated by G-proteins, divalent cations, and pH.
- The physiological significance of these findings requires further exploration.